These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 10594984)

  • 1. By the way, doctor. I am 47 and have been taking Loestrin 1/20 for the past seven months. After the first month, I ceased having periods, which my gynecologist says is typical. Could you comment on why this happens and whether I am putting myself at increased risk for uterine cancer?
    Robb-Nicholson C
    Harv Womens Health Watch; 2000 Jan; 7(5):8. PubMed ID: 10594984
    [No Abstract]   [Full Text] [Related]  

  • 2. Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LO.
    Poindexter AN; Burkman R; Fisher AC; LaGuardia KD
    Int J Fertil Womens Med; 2003; 48(4):163-72. PubMed ID: 13677549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three new combination oral contraceptives: Seasonique, Loestrin 24 Fe, and Yaz.
    Med Lett Drugs Ther; 2006 Sep; 48(1244):77-8. PubMed ID: 17001297
    [No Abstract]   [Full Text] [Related]  

  • 4. Metabolic effects and efficacy of a triphasic oral contraceptive (norgestimate/ethinyl estradiol).
    Andolsek KM; Burkman RT; Kafrissen ME; Olson W; Osterman J
    Int J Fertil Menopausal Stud; 1993; 38 Suppl 3():122-5. PubMed ID: 8260970
    [No Abstract]   [Full Text] [Related]  

  • 5. By the way, doctor. I have recently lost a cousin in her mid-forties to melanoma. She was fair-skinned and had a family history of melanoma and other cancers. Doctors suggested there might be a connection between her oral contraceptive, Loestrin, and the melanoma. Could this be true?
    Nicholson CR
    Harv Womens Health Watch; 1999 Sep; 7(1):8. PubMed ID: 10445996
    [No Abstract]   [Full Text] [Related]  

  • 6. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A new 2-step combination preparation for hormonal contraception].
    James A
    Schweiz Rundsch Med Prax; 1982 Dec; 71(51):1990-3. PubMed ID: 7163134
    [No Abstract]   [Full Text] [Related]  

  • 8. A clinical overview of a new triphasic contraceptive containing gestodene.
    Christie T
    Int J Fertil; 1989 Sep; 34 Suppl():40-9. PubMed ID: 2576257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical and biological justifications for the use of Triella].
    McGuire JL; Pasquale SA; Castaigne JP
    Rev Fr Gynecol Obstet; 1986 Dec; 81(12):731-6. PubMed ID: 3823727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical results with a new low dose oral contraceptive utilizing norethindrone/ethinyl estradiol.
    Pasquale SA; Yuliano E
    Contraception; 1975 Nov; 12(5):495-503. PubMed ID: 1192736
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of two monophasic oral contraceptives: gestodene/ethinyl estradiol versus desogestrel/ethinyl estradiol.
    Benagiano G
    Int J Fertil; 1989 Sep; 34 Suppl():31-9. PubMed ID: 2576255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reference period analysis of vaginal bleeding with triphasic oral contraceptive agents containing norethindrone or levonorgestrel: a comparison study.
    Schwarz BE; Pierce C; Walden CE; Knopp RH
    Int J Fertil; 1992; 37(3):176-82. PubMed ID: 1355765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel.
    Ahrendt HJ; Makalová D; Parke S; Mellinger U; Mansour D
    Contraception; 2009 Nov; 80(5):436-44. PubMed ID: 19835717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical study of a low-dose contraceptive--Femodene].
    Rachev E; Damianov L; Dukovski A; Katsarova M
    Akush Ginekol (Sofiia); 1995; 34(3):71-3. PubMed ID: 8787249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe).
    Nakajima ST; Archer DF; Ellman H
    Contraception; 2007 Jan; 75(1):16-22. PubMed ID: 17161118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hormonal contraceptives in female rowers].
    Lisý Z
    Cas Lek Cesk; 1984 Aug; 123(35):1086-90. PubMed ID: 6498900
    [No Abstract]   [Full Text] [Related]  

  • 17. Scheduled and unscheduled bleeding patterns with two combined hormonal contraceptives: application of new recommendations for standardization.
    Hampton RM; Fisher AC; Pagano S; LaGuardia KD
    Fertil Steril; 2009 Aug; 92(2):434-40. PubMed ID: 18930189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive.
    Anttila L; Kunz M; Marr J
    Contraception; 2009 Nov; 80(5):445-51. PubMed ID: 19835718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy and safety of drospirenone-ethinylestradiol on contraception in healthy Chinese women: a multicenter randomized controlled trial].
    Fan GS; Bian ML; Cheng LN; Cao XM; Huang ZR; Han ZY; Jing XP; Li J; Wu SY; Xiong CL; Xiong ZA; Yue TF
    Zhonghua Fu Chan Ke Za Zhi; 2009 Jan; 44(1):38-44. PubMed ID: 19563061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Progress in oral contraception. Advantages of a levonorgestrel-containing 3-stage preparation over low-dose levonorgestrel and desogestrel containing monophasic combination preparations].
    Lachnit-Fixson U
    Fortschr Med; 1984 Sep; 102(33):825-30. PubMed ID: 6383993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.